►个人简介

工作职位：制药工程教研室副教授，硕士生导师

办公地址：青岛科技大学CCF大楼1101

工作邮箱：shanshandu000@163.com

2011.06硕士毕业于山东大学药学院，2015.01博士毕业于德国海德堡大学，2015.03-2017.03在清华大学生物化工专业从事博士后研究工作，2017.04-2018.09在药明生物从事细胞培养与工艺开发工作。2018.09来校工作至今，目前主要从事多糖及多肽类药物的研发工作。发表学术论文20余篇，已发表学术期刊包括Bioorg Chem, Carbohydr Polym, Sci China Chem, Dyes Pigments, Acta Pharmacol Sin, Thromb Haemost, Glycoconj J, J Pept Sci等。获得国家自然青年科学基金项目1项，山东省基金1项，中国博士后基金1项。

►教学情况

1、本科生课程

药物分析：32课时，本科生，约60人。

►论文

[1] Chi QN, Du S*, et al. Efficient synthesis and anticancer evaluation of spider toxin peptide LVTX-8-based analogues with enhanced stability. [J] Bioorg Chem, 2023, 134, 106451

[2] Du S*, Wang SN, et al. Significantly different fluorescent responses of two aggregation-induced emission probes to heparin. [J] Dyes Pigments, 2022, 207, 110767

[3] Yin H, Du S*, et al. The hybrid oncolytic peptide NTP-385 potently inhibits adherent cancer cells by targeting the nucleus, Acta Pharmacol Sin, 2023, 44, 201-210

[4] Jia SX, Du S*, et al. Binding ability of methylene blue with heparin dependent on its sulfate level rather than its sulfation location or basic saccharide structure [J] Glycoconj J, 2021, 38(5): 551

[5] Yin H, Du S*, et al. Hybrid peptide NTP-217 triggers ROS-mediated rapid necrosis in liver cancer cells by induction of mitochondrial leakage, [J] Front Oncol, 2023, 1028600

[6] Qi YK*, Du S*, et al. Discovery, synthesis, and optimization of teixobactin, a novel antibiotic without detectable bacterial resistance J Pept Sci, 2022, 24, e3428.

[7] Chen XT, Du S*, Qi YK*, et al. DIC/Oxyma based accelerated synthesis and oxidative folding studies of centipede toxin RhTx, [J] J Pept Sci, 2021, e3368

[8] Yan YS#, Du S#, Yang J, et al. Discovery of enzymatically depolymerized heparins capable of treating Bleomycin-induced pulmonary injury and fibrosis in mice. [J] Carbohydr Polym, 2017 June, 174: 82-88

[9] Du S, Krämer S, Harenberg J, et al. Chromogenic assays for measurement rivaroxaban from EDTA anticoagulated plasma samples [J]. Thromb Haemost. 2015, Jan 113(5): 1149

[10] Du S, Weiss C, Harenberg J, et al. Determination of dabigatran concentrations in patient plasma, serum and urine samples: comparison of six methods [J]. Clin Chem Lab Med, 2015, Jul 53(8):1237

[11] Du S, Harenberg J, Krämer S, et al. Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method [J]. Ther Drug Monit. 2015 Jun, 37(3):375

[12] Qi YK, Si Y, Du S, et al. Recent advances in the chemical synthesis and semi-synthesis of poly-ubiquitin-based proteins and probes. [J] Sci China Chem, 2019 Jan, 62: 299-312

[13] Harenberg J, Du S, et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study [J]. Clin Chem Lab Med, 2016 Feb, 54(2):275-83

[14] Harenberg J, Du S, et al. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants [J]. Semin Thromb Hemost. 2015 Mar, 41(2):228-36.

[15] Harenberg J, Du S, Weiss C, et al. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH [J], J Thromb Haemost, 2014 May, 12: 801-804.

[16] Du S, Harenberg J, Krämer S, Marx S, et al. Determination of dabigatran and rivaroxaban in serum samples from patients on treatment. Poster session presented at: ISTH 24th Congress, 2013 June 29 - July 4; Amsterdan.

[17] Harenberg J, Kramer S, Du S, et al. Measurement of rivaroxaban and apixaban in serum samples of patients [J]. Eur J Clin Invest. 2014 Aug, 44 (8):743–52.

[18] Harenberg J, Krämer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples [J], Semin Thromb Hemost. 2014 Feb, 40 (1):129 - 34.

[19] Harenberg J, Du S, Krämer S, et al. Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples [J], Semin Thromb Hemost 2013 Feb, 39: 66-71.

[20] Harenberg J, Krämer S, Du S, et al. Concept of a point of care test to detect new oral anticoagulants in urine samples [J], Thrombosis Journal 2013 Aug, 11: 15.

[14] Yan YS, Guan CG, Du S, et al. Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis. [J] Front in pharmacol, 2017 Aug, 8:514

[21] Li Y, Luo JY, Cui HF, Zheng L, Du S, et al. Study on anti-metasis of heparin derivatives as ligand antagonist of p-selectin [J]. Biomed Pharmacother 2010 Dec, 64: 654-658.

[22]杜姗姗,崔慧斐.低分子肝素分子量测定方法[J],药物分析杂志, 2011, 31(2): 402-408.

[23]杜姗姗,桑青,崔慧斐.低分子肝素分子量测定用对照品的研制[J],药物分析杂志, 2012, 32 (11): 1976–1980.

►承担的科研项目

[1] 202101-202312，国自然青年科学基金项目，82003647，肝素非抗凝活性治疗特发性肺纤维化及作用机制研究，在研，项目负责人。

[2] 201907-202206，山东省基金，ZR2019BH045，肝素及其衍生物对脓毒症治疗作用的研究，在研，项目负责人。

[3] 2016.01–2017.12，中国博士后基金，2015M581121，肝素的修饰及其对治疗特发性肺纤维化影响规律的研究，已结题，项目负责人。